Diabetes, Vol 37, Issue 11 1549-1558, Copyright © 1988 by American Diabetes Association

ARTICLES

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

T Fujiwara, S Yoshioka, T Yoshioka, I Ushiyama and H Horikoshi
Biological Research Laboratories, Sankyo Company, Ltd., Tokyo, Japan.

CS-045 is a new oral antidiabetic agent that was effective in insulin-resistant diabetic animal models, including the KK mouse, the ob/ob mouse, and the Zucker fatty rat. CS-045 was not effective in the streptozocin-treated mouse, an insulin-deficient diabetic animal model. In fed KK mice, CS-045 lowered the plasma glucose levels in a dose-dependent manner after a single oral administration, and the hypoglycemic effect lasted for at least 18 h. In normal rats, however, plasma glucose levels were not changed after administration of CS-045. CS-045 when given chronically (2 wk) to diabetic KK and ob/ob mice as a 0.2% food admixture dramatically improved hyperglycemia, hyperinsulinemia, and hypertriglyceridemia to near-normal values and decreased plasma lactate, free fatty acid, and ketone body levels without reducing food intake or body weight. In the obese Zucker fatty rat, oral administration of CS-045 had a similar effect in lowering plasma glucose, insulin, triglyceride, free fatty acid, lactate, and ketone body levels. The CS-045-treated Zucker fatty rats showed increased glucose tolerance and decreased insulin secretion in response to oral glucose. After 9 days of treatment, insulin binding to adipocyte plasma membranes from both CS-045-treated Zucker fatty rats and KK mice was increased. Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left. These findings suggest that CS-045 increases not only insulin sensitivity but also insulin responsiveness. Based on its pharmacological profile, CS-045 is a new orally effective antidiabetic agent that may reduce abnormalities of glucose and lipid metabolism in obese and non-insulin-dependent diabetes mellitus patients with insulin resistance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. J. Lessard, Z.-P. Chen, M. J. Watt, M. Hashem, J. J. Reid, M. A. Febbraio, B. E. Kemp, and J. A. Hawley Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E251 - E257. [Abstract] [Full Text] [PDF]

				R. Maniratanachote, K. Minami, M. Katoh, M. Nakajima, and T. Yokoi Chaperone Proteins Involved in Troglitazone-Induced Toxicity in Human Hepatoma Cell Lines Toxicol. Sci., February 1, 2005; 83(2): 293 - 302. [Abstract] [Full Text] [PDF]

				E. Santini, P. Fallahi, S. M. Ferrari, A. Masoni, A. Antonelli, and E. Ferrannini Effect of PPAR-{gamma} Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells Diabetes, December 1, 2004; 53(suppl_3): S79 - S83. [Abstract] [Full Text] [PDF]

				S. D. Patel, M. W. Rajala, L. Rossetti, P. E. Scherer, and L. Shapiro Disulfide-Dependent Multimeric Assembly of Resistin Family Hormones Science, May 21, 2004; 304(5674): 1154 - 1158. [Abstract] [Full Text] [PDF]

				H.-i. Kim and Y.-h. Ahn Role of Peroxisome Proliferator-Activated Receptor-{gamma} in the Glucose-Sensing Apparatus of Liver and {beta}-Cells Diabetes, February 1, 2004; 53(90001): S60 - 65. [Abstract] [Full Text]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				K. T. Iida, Y. Kawakami, M. Suzuki, H. Shimano, H. Toyoshima, H. Sone, K. Shimada, Y. Iwama, Y. Watanabe, H. Mokuno, et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1125 - E1130. [Abstract] [Full Text] [PDF]

				B. Kalderon, N. Mayorek, L. Ben-Yaacov, and J. Bar-Tana Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E795 - E803. [Abstract] [Full Text] [PDF]

				P. D. G. Miles, Y. Barak, R. M. Evans, and J. M. Olefsky Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E618 - E626. [Abstract] [Full Text] [PDF]

				Y. Watanabe, M. Nakajima, and T. Yokoi Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10 Drug Metab. Dispos., December 1, 2002; 30(12): 1462 - 1469. [Abstract] [Full Text] [PDF]

				T. Albrektsen, K. S. Frederiksen, W. E. Holmes, E. Boel, K. Taylor, and J. Fleckner Novel Genes Regulated by the Insulin Sensitizer Rosiglitazone During Adipocyte Differentiation Diabetes, April 1, 2002; 51(4): 1042 - 1051. [Abstract] [Full Text] [PDF]

				T. P. Combs, J. A. Wagner, J. Berger, T. Doebber, W.-J. Wang, B. B. Zhang, M. Tanen, A. H Berg, S. O'Rahilly, D. B. Savage, et al. Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR{gamma} Agonists: A Potential Mechanism of Insulin Sensitization Endocrinology, March 1, 2002; 143(3): 998 - 1007. [Abstract] [Full Text] [PDF]

				H.-i. Kim, J.-Y. Cha, S.-Y. Kim, J.-w. Kim, K. J. Roh, J.-K. Seong, N. T. Lee, K.-Y. Choi, K.-S. Kim, and Y.-h. Ahn Peroxisomal Proliferator-Activated Receptor-{gamma} Upregulates Glucokinase Gene Expression in {beta}-Cells Diabetes, March 1, 2002; 51(3): 676 - 685. [Abstract] [Full Text] [PDF]

				Y. Yamamoto, H. Yamazaki, T. Ikeda, T. Watanabe, H. Iwabuchi, M. Nakajima, and T. Yokoi Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells Drug Metab. Dispos., February 1, 2002; 30(2): 155 - 160. [Abstract] [Full Text] [PDF]

				Y.-B. Kim, T. P. Ciaraldi, A. Kong, D. Kim, N. Chu, P. Mohideen, S. Mudaliar, R. R. Henry, and B. B. Kahn Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects Diabetes, February 1, 2002; 51(2): 443 - 448. [Abstract] [Full Text] [PDF]

				M. Shintani, H. Nishimura, S. Yonemitsu, Y. Ogawa, T. Hayashi, K. Hosoda, G. Inoue, and K. Nakao Troglitazone Not Only Increases GLUT4 but Also Induces Its Translocation in Rat Adipocytes Diabetes, October 1, 2001; 50(10): 2296 - 2300. [Abstract] [Full Text]

				B. Brunmair, F. Gras, S. Neschen, M. Roden, L. Wagner, W. Waldhausl, and C. Furnsinn Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Changes in Gene Expression Diabetes, October 1, 2001; 50(10): 2309 - 2315. [Abstract] [Full Text]

				H. S. Camp, A. Chaudhry, and T. Leff A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor {{gamma}} Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes Endocrinology, July 1, 2001; 142(7): 3207 - 3213. [Abstract] [Full Text] [PDF]

				I. Yokoyama, K. Yonekura, T. Moritan, M. Tateno, T. Momose, K. Ohtomo, Y. Inoue, and R. Nagai Troglitazone Improves Whole-Body Insulin Resistance and Skeletal Muscle Glucose Use in Type II Diabetic Patients J. Nucl. Med., July 1, 2001; 42(7): 1005 - 1010. [Abstract] [Full Text] [PDF]

				N. D. Oakes, P. G. Thalén, S. M. Jacinto, and B. Ljung Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability Diabetes, May 1, 2001; 50(5): 1158 - 1165. [Abstract] [Full Text]

				M. Inoue, H. Itoh, T. Tanaka, T.-H. Chun, K. Doi, Y. Fukunaga, N. Sawada, J. Yamshita, K. Masatsugu, T. Saito, et al. Oxidized LDL Regulates Vascular Endothelial Growth Factor Expression in Human Macrophages and Endothelial Cells Through Activation of Peroxisome Proliferator-Activated Receptor-{{gamma}} Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 560 - 566. [Abstract] [Full Text] [PDF]

				H. Morita, Y. Oki, T. Ito, H. Ohishi, S. Suzuki, and H. Nakamura Administration of Troglitazone, but Not Pioglitazone, Reduces Insulin Resistance Caused by Short-Term Dexamethasone (DXM) Treatment by Accelerating the Metabolism of DXM Diabetes Care, April 1, 2001; 24(4): 788 - 789. [Full Text]

				J. M. Way, W. W. Harrington, K. K. Brown, W. K. Gottschalk, S. S. Sundseth, T. A. Mansfield, R. K. Ramachandran, T. M. Willson, and S. A. Kliewer Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor {{gamma}} Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues Endocrinology, March 1, 2001; 142(3): 1269 - 1277. [Abstract] [Full Text] [PDF]

				Z. Chen, S. Ishibashi, S. Perrey, J.-i. Osuga, T. Gotoda, T. Kitamine, Y. Tamura, H. Okazaki, N. Yahagi, Y. Iizuka, et al. Troglitazone Inhibits Atherosclerosis in Apolipoprotein E-Knockout Mice : Pleiotropic Effects on CD36 Expression and HDL Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 372 - 377. [Abstract] [Full Text] [PDF]

				I. Gabriely, R. Wozniak, M. Hawkins, and H. Shamoon Troglitazone Amplifies Counterregulatory Responses to Hypoglycemia in Nondiabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 521 - 528. [Abstract] [Full Text]

				U. SMITH, S. GOGG, A. JOHANSSON, T. OLAUSSON, V. ROTTER, and B. SVALSTEDT Thiazolidinediones (PPAR{gamma} agonists) but not PPAR{alpha} agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes FASEB J, January 1, 2001; 15(1): 215 - 220. [Abstract] [Full Text] [PDF]

				V. E. Kostrubsky, J. F. Sinclair, V. Ramachandran, R. Venkataramanan, Y. H. Wen, E. Kindt, V. Galchev, K. Rose, M. Sinz, and S. C. Strom The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures Drug Metab. Dispos., October 1, 2000; 28(10): 1192 - 1197. [Abstract] [Full Text] [PDF]

				T. Kakuma, Y. Lee, M. Higa, Z.-w. Wang, W. Pan, I. Shimomura, and R. H. Unger Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets PNAS, July 18, 2000; 97(15): 8536 - 8541. [Abstract] [Full Text] [PDF]

				C. Fürnsinn, B. Brunmair, S. Neschen, M. Roden, and W. Waldhäusl Troglitazone Directly Inhibits CO2 Production from Glucose and Palmitate in Isolated Rat Skeletal Muscle J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 487 - 493. [Abstract] [Full Text]

				V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator-Activated Receptor-{gamma} Activators Circulation, January 25, 2000; 101(3): 235 - 238. [Abstract] [Full Text] [PDF]

				M. Higa, Y.-T. Zhou, M. Ravazzola, D. Baetens, L. Orci, and R. H. Unger Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats PNAS, September 28, 1999; 96(20): 11513 - 11518. [Abstract] [Full Text] [PDF]

				M. Hosokawa, H. Tsukada, K. Fukuda, M. Oya, M. Onomura, H. Nakamura, M. Kodama, Y. Yamada, and Y. Seino Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1080 - 1084. [Abstract] [Full Text]

				J. R. Zierath, J. W. Ryder, T. Doebber, J. Woods, M. Wu, J. Ventre, Z. Li, C. McCrary, J. Berger, B. Zhang, et al. Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR{gamma} Agonist) Action Endocrinology, December 1, 1998; 139(12): 5034 - 5041. [Abstract] [Full Text] [PDF]

				L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]

				K. S. Park, T. P. Ciaraldi, K. Lindgren, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, S. R. Tufari, J. H. Veerkamp, A. Vidal-Puig, and R. R. Henry Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-{gamma} J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2830 - 2835. [Abstract] [Full Text]

				Y.-T. Zhou, M. Shimabukuro, M.-Y. Wang, Y. Lee, M. Higa, J. L. Milburn, C. B. Newgard, and R. H. Unger Role of peroxisome proliferator-activated receptor alpha  in disease of pancreatic beta  cells PNAS, July 21, 1998; 95(15): 8898 - 8903. [Abstract] [Full Text] [PDF]

				A. Ikeda, K.-T. Chang, Y. Matsumoto, Y. Furuhata, M. Nishihara, F. Sasaki, and M. Takahashi Obesity and Insulin Resistance in Human Growth Hormone Transgenic Rats Endocrinology, July 1, 1998; 139(7): 3057 - 3063. [Abstract] [Full Text] [PDF]

				K. S. Park, T. P. Ciaraldi, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, and R. R. Henry Troglitazone Regulation of Glucose Metabolism in Human Skeletal Muscle Cultures from Obese Type II Diabetic Subjects J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1636 - 1643. [Abstract] [Full Text]

				S. Schwartz, P. Raskin, V. Fonseca, J. F. Graveline, and The Troglitazone and Exogenous Insulin Study Group Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 861 - 866. [Abstract] [Full Text] [PDF]

				H. Imura A Novel Antidiabetic Drug, Troglitazone -- Reason for Hope and Concern N. Engl. J. Med., March 26, 1998; 338(13): 908 - 909. [Full Text]

				M. Shimabukuro, Y.-T. Zhou, M. Levi, and R. H. Unger Fatty acid-induced beta  cell apoptosis: A link between obesity and diabetes PNAS, March 3, 1998; 95(5): 2498 - 2502. [Abstract] [Full Text] [PDF]

				R. L. Prigeon, S. E. Kahn, and D. Porte Jr. Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 819 - 823. [Abstract] [Full Text]

				M. Shimabukuro, Y.-T. Zhou, Y. Lee, and R. H. Unger Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats J. Biol. Chem., February 6, 1998; 273(6): 3547 - 3550. [Abstract] [Full Text] [PDF]

				K.-I. Ohtani, H. Shimizu, N. Sato, and M. Mori Troglitazone (CS-045) Inhibits {beta}-Cell Proliferation Rate Following Stimulation of Insulin Secretion in HIT-T 15 Cells Endocrinology, January 1, 1998; 139(1): 172 - 178. [Abstract] [Full Text] [PDF]

				A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]

				K. Izumino, H. Sakamaki, M. Ishibashi, H. Takino, H. Yamasaki, Y. Yamaguchi, N. Chikuba, K. Matsumoto, S. Akazawa, K. Tokuyama, et al. Troglitazone Ameliorates Insulin Resistance in Patients with Werner's Syndrome J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2391 - 2395. [Abstract] [Full Text] [PDF]

				T. Izumi, K. Hosiyama, S. Enomoto, K. Sasahara, and Y. Sugiyama Pharmacokinetics of Troglitazone, an Antidiabetic Agent: Prediction of In Vivo Stereoselective Sulfation and Glucuronidation from In Vitro Data J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1392 - 1400. [Abstract] [Full Text]

				H. Maegawa, R. Ide, M. Hasegawa, S. Ugi, K. Egawa, M. Iwanishi, R. Kikkawa, Y. Shigeta, and A. Kashiwagi Thiazolidine Derivatives Ameliorate High Glucose-induced Insulin Resistance via the Normalization of Protein-tyrosine Phosphatase Activities J. Biol. Chem., March 31, 1995; 270(13): 7724 - 7730. [Abstract] [Full Text] [PDF]

				J. J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone N. Engl. J. Med., November 3, 1994; 331(18): 1188 - 1193. [Abstract] [Full Text]

				H. Keen Insulin Resistance and the Prevention of Diabetes Mellitus N. Engl. J. Med., November 3, 1994; 331(18): 1226 - 1227. [Full Text]

				H. Nishizawa, K. Yamagata, I. Shimomura, M. Takahashi, H. Kuriyama, K. Kishida, K. Hotta, H. Nagaretani, N. Maeda, M. Matsuda, et al. Small Heterodimer Partner, an Orphan Nuclear Receptor, Augments Peroxisome Proliferator-activated Receptor gamma Transactivation J. Biol. Chem., January 4, 2002; 277(2): 1586 - 1592. [Abstract] [Full Text] [PDF]